Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nanoviricides Inc (NY: NNVC )

1.280 -0.050 (-3.76%)
Official Closing Price Updated: 6:30 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nanoviricides Inc

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
NanoViricides Signs a License Agreement That Includes Clinical Evaluation of Its COVID-19 Drug Candidates
Via ACCESSWIRE
COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All
COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All 
Via News Direct
Exposures COVID-19
COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All
By David Willey, Benzinga 
Via TheNewswire.com
Exposures COVID-19
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats 
Via News Direct
Topics Death Economy
Exposures COVID-19 Death Economy
This Company Is Looking For A Monkeypox Drug As City Investigates Deaths
Learn more about NanoViricides, Inc. by gaining access to the latest research report 
Via TheNewswire.com
Topics Death
Exposures COVID-19 Death
NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly
Learn More about NanoViricides, Inc. by gaining access to the latest research report 
Via TheNewswire.com
Short Volatility Alert: NanoViricides, Inc.
On Thursday, shares of NanoViricides, Inc. (NYSE: NNVC) experienced volatile short activity. After the activity, the stock price went up +48.37% to $3.65. The overall sentiment for NNVC has been... 
Via Benzinga
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
By Ernest Dela Aglanu, Benzinga 
Via TheNewswire.com
Topics Death Economy
Exposures COVID-19 Death Economy
With Nearly 20,000 Americans Still Hospitalized, COVID Remains A Threat – NanoViricides Gets Ready To Begin Clinical Trials For The World To Defeat It
With Nearly 20,000 Americans Still Hospitalized, COVID Remains A Threat – NanoViricides Gets Ready To Begin Clinical Trials For The World To Defeat It 
Via News Direct
Topics Death
Exposures COVID-19 Death
With Nearly 20,000 Americans Still Hospitalized, COVID Remains A Threat – NanoViricides Gets Ready To Begin Clinical Trials For The World To Defeat It
By Ernest Dela Aglanu, Benzinga 
Via TheNewswire.com
Topics Death
Exposures COVID-19 Death
With Nearly 20,000 Americans Still Hospitalized, COVID Remains A Threat – NanoViricides Gets Ready To Begin Clinical Trials For The World To Defeat It, And To Prepare For Battling Against The Next Likely Coronavirus Pandemic
Read the latest report on NanoViricides, Inc (NYSE: NNVC) here. 
Via Benzinga
uniQure To Rally Around 162%? Here Are 10 Other Analyst Forecasts For Tuesday
UBS cut the price target for Honeywell International Inc. (NASDAQ: HON) from $193 to $185. UBS analyst Chris Snyder maintained a Sell rating. Honeywell shares fell 0.2% to $191.99 in pre-market... 
Via Benzinga
NanoViricides Has Filed its Quarterly Report - Company has Begun Production of Coronavirus Drug for Clinical Trials
Via ACCESSWIRE
NanoViricides, Inc. to Present at the Biotech Showcase(TM) 2023 Conference in San Fransisco on January 9th at 10:30am PT
Via ACCESSWIRE
NanoViricides, Inc. to Present at the RHK Capital Disruptive Growth Conference in New York City on December 6th at 1:20pm ET
Via ACCESSWIRE
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027
EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END 
Via FinancialNewsMedia
NanoViricides, Inc. Has Filed its Quarterly Report: Coronavirus Drug NV-CoV-2 IND Stage
Via ACCESSWIRE
7 Speculative Penny Stocks Under $3 That Deserve Your Attention in Nov.
While penny stocks are highly speculative and risky, you may still want to consider these seven opportunities. 
Via InvestorPlace
This Company Is Looking For A Monkeypox Drug As City Investigates Deaths
By David Willey, Benzinga 
Via News Direct
Topics Death
Exposures COVID-19 Death
This Company Is Looking For A Monkeypox Drug As City Investigates Deaths
New York City is investigating the cause of death for two people who died after contracting monkeypox. 
Via Benzinga
NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug NV-CoV-2 IND Stage
Via ACCESSWIRE
NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly
By Rachael Green, Benzinga 
Via News Direct
Monkeypox Is Popping Up In Places It Shouldn't But NanoViricides Says It May Have A Solution
More than 30,000 confirmed or suspected cases of monkeypox have been reported across 93 countries in the world. While those numbers are still small scientists are now concerned that this sudden and... 
Via Benzinga
NanoViricides Provides Additional Details on Its Rapid Monkeypox Drug Strategy
Via ACCESSWIRE
NanoViricides Initiates New Drug Development To Combat Monkeypox Virus
NanoViricides, Inc. (NYSE American: NNVC) reports that it has begun drug development to combat the monkeypox virus. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning! It's time for another dive into the biggest pre-market stock movers as we see what's affecting shares on Thursday! 
Via InvestorPlace
Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per share... 
Via Benzinga
Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session
Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday. 
Via Benzinga
NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox Virus
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback